The growing need for oligonucleotide therapeutics aimed at larger patient populations has driven the demand for high-quality nucleoside phosphoramidite which are building blocks for oligonucleotide therapeutics.
The global oligonucleotide therapeutics market is projected to grow by USD 13.44 billion between 2022 and 2027, at a compound annual growth rate (CAGR) of 19.87%, according to a report by Technavio. This growth, driven by the expanding
RNA-based therapeutic modalities, has placed pressure on suppliers to provide consistent, high-purity phosphoramidites for large-scale manufacturing. The limited number of reliable suppliers further complicates this challenge, particularly as more companies scale up for clinical trials and commercial manufacturing…
Resources
The Role of Benchmarking Critical Impurity Control in Therapeutic Oligonucleotide Phosphoramidites
- 2024-12-11
